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Background: Breast-conserving therapy, consisting of lumpectomy and adjuvant radiotherapy, is con-
sidered standard treatment for early-stage breast cancer. One of the most important risk factors of local
recurrence is the presence of positive surgical margins following lumpectomy. We aimed to develop and
validate a predictive model (nomogram) to predict for positive margins following the ﬁrst attempt at
lumpectomy as a preoperative tool for clinical decision-making.
Methods: Patients with clinical T1e2N0e1Mxe0 histology-proven invasive breast carcinoma who under-
went BCT throughout the North-East region of The Netherlands between June 2008 and July 2009 were
selected from the Netherlands Cancer Registry (n ¼ 1185). Results from multivariate logistic regression
analyses served as the basis for development of the nomogram. Nomogram calibration and discrim-
ination were assessed graphically and by calculation of a concordance index, respectively. Nomogram
performance was validated on an external independent dataset (n ¼ 331) from the University Medical
Center Groningen.
Results: The ﬁnal multivariate regression model included clinical, radiological, and pathological variables.
Concordance indices were calculated of 0.70 (95% CI: 0.66e0.74) and 0.69 (95% CI: 0.63e0.76) for the
modeling and the validation group, respectively. Calibration of the model was considered adequate in
both groups. A nomogram was developed as a graphical representation of the model. Moreover, a web-
based application (http://www.breastconservation.com) was build to facilitate the use of our nomogram
in a clinical setting.
Conclusion: We developed and validated a nomogram that enables estimation of the preoperative risk of
positive margins in breast-conserving surgery. Our nomogram provides a valuable tool for identifying
high-risk patients who might beneﬁt from preoperative MRI and/or oncoplastic surgery.
 2013 Elsevier Ltd. All rights reserved.Introduction
Breast-conserving therapy (BCT), consisting of lumpectomy and
adjuvant radiotherapy, is considered standard treatment for early-
stage breast cancer.1,2 The presence of a positive (surgical) margin,
usually deﬁned as tumor cells being present at the inked margin oferating characteristic curve;
iopsy; LR, local recurrence;
.
þ31 50 3614873.
am).
All rights reserved.the lumpectomy specimen, has been reported to be the most
consistent risk factor for local recurrence (LR) following BCT.3,4 The
percentage of patients with positive margins following the ﬁrst
attempt at lumpectomy ranges from 20 to 40% in the majority of
studies.5 To reduce the risk of LR in the case of positive margins,
additional surgery and/or radiotherapy are required with adverse
affects on cosmesis, psychological distress, and health costs.6
Previous studies reported large tumor size, lobular histological
type, positive N-stage, multifocal disease, lymphovascular invasion,
co-existing ductal carcinoma in situ (DCIS), microcalciﬁcations on
mammography, and young age to be independent risk factors asso-
ciated with positive margins following lumpectomy (Supplemental
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factors, statistical tools can be applied to calculate the overall prob-
ability of a speciﬁc outcome.7 These so-called nomograms are tail-
ored to the proﬁle of an individual patient.8 User-friendly graphical
interfaces and web-based calculators can facilitate the use of no-
mograms in clinical practice.
Several nomograms have been developed in the ﬁeld of breast
cancer, including one for predicting the risk of positive surgical
margins after BCT.9 However, this study was based and validated on
single-center data, which might impair generalizability of the
model. The aims of the current study were: i) to develop a user-
friendly graphical and web-based nomogram based on multi-
center data to predict individual probability of positive margins
following the ﬁrst attempt at lumpectomy based on clinicopatho-
logical variables and ii) to validate the nomogram in an indepen-
dent dataset.
Methods
Patient population
A modeling and a validation group were constituted for devel-
opment and validation of the nomogram, respectively. The mod-
eling group consisted of breast cancer patients selected from the
Netherlands Cancer Registry (NCR). Based on pathological notiﬁ-
cation through the PALGA (automated pathology archive) system,10
trained registration clerks gathered data concerning patient, tumor,
and treatment characteristics from the patient ﬁles. Additionally,
the NCR registered surgical margin status following lumpectomy
between June 2008 and July 2009. During this time frame, data was
collected from 1495 patients who underwent BCT in one of 24 in-
stitutions throughout the North-East region of the Netherlands.
Supplemental radiological and clinical variables were collected
retrospectively for 1349 patients from 20 out of 24 institutions.
Three institutions were excluded due to a relatively limited con-
tribution to theNCRdatabase (<15 patients). One institution did not
participate because of a change in the preoperative work-up during
the investigated time frame, which might have inﬂuenced surgical
outcome. Approval was obtained from the institutional review
board of all participating institutions prior to initiation of the study.
Women with clinical T1e2N0e1Mxe0 histology-proven invasive
breast carcinoma who underwent BCT were included in the study.
Patients with unconﬁrmed malignancy prior to surgery, undeﬁned
margin status, neo-adjuvant treatment, or absence of reported
radiological tumor size were excluded. A total of 1185 out of 1349
patients (88%) were eligible for the modeling group.
The validation group consisted of 439 patients who underwent
BCT at the University Medical Center Groningen (UMCG), Gronin-
gen, The Netherlands between July 2004 and June 2008 or July
2009 and May 2011. Patients who underwent BCT between June
2008 and July 2009 were assigned to the modeling group as they
were part of the NCR database. Inclusion and exclusion criteria
were identical to those applied in themodeling group. A total of 331
patients (75%) were eligible for the validation group.
Clinicopathological evaluation
The following variables were incorporated from the NCR data-
base: surgical margin status, age, preoperative N-stage, preopera-
tive T-stage, tumor location, histological type, histological grade,
estrogen receptor (ER) status, progesterone receptor (PR) status,
Her2/neu receptor status, and presence of co-existing DCIS.
Positive surgical margin status was deﬁned as microscopically
conﬁrmed invasive carcinoma (IC) and/or DCIS at the inked margin
of the lumpectomy specimen following the ﬁrst attempt atlumpectomy. Staging was performed according to the ﬁfth edition
of the TNM atlas. Preoperative T-stage was based on the maximum
tumor diameter as measured on MRI (if available) or
ultrasonography. Preoperative N-stage was based on clinical and/or
radiological examination as well as preoperative histological ex-
amination (if available) of the axillary region. Topography and
morphology were coded according to the International Classi-
ﬁcation of Diseases for Oncology (ICD-O).11 Grading of invasive
carcinoma was scored according to the Nottingham (Elston-Ellis)
modiﬁcation of the ScarfeBloomeRichardson grading system.
Positivity of estrogen and progesterone receptors was deﬁned as at
least 10% of immunostained nuclei of tumor cells. HER2/neu status
was considered positive in case of Her2/neu 3þ (strong and com-
plete membranous expression in >30% of tumor cells) or Her2/neu
2þ (weak complete membranous expression in >10% of tumor
cells) conﬁrmed with positive ﬂuorescence in situ hybridization.
Co-existing DCIS was deﬁned as the presence of any DCIS compo-
nent. All pathological variables were assessed on ﬁnal pathology
due to the fact that no preoperative core needle biopsy (CNB) was
routinely performed in the vast majority of patients.
The NCR database was supplemented with data collected from
patient ﬁles at the participating institutions, including clinical
(family history, referral from screening, palpability, breast cup size,
andprior surgery to the ipsilateral breast), and radiological variables
(BI-RADS classiﬁcation, suspicion ofmultifocality, preoperativeMRI,
microcalciﬁcations, density of the breast, and area of the breast on
the preoperative digitalmammogram). Family historywas recorded
as negative, ﬁrst-degree (FDR), or second-degree relatives (SDR).
Tumors were classiﬁed as non-palpable if a needle-localization
procedure was required for excision. BI-RADS classiﬁcation was
recorded according to the fourth edition of the Breast Imaging
Reporting andData System.12 Suspicion ofmultifocalitywas deﬁned
as the presence of two ormore tumor foci within the same quadrant
of the ipsilateral breast as assessed on MRI (if available) or
radiography. The presence of microcalciﬁcations was assessed on
mammography and reported as present or absent. Density of the
breast was assessed on mammograms and reported as one out of
four BI-RADS categories: mostly fatty (0e25% dense), scattered
ﬁbroglandular tissue (25e50% dense), heterogeneously dense (50e
75% dense), and extremely dense (75e100% dense).12 Area of the
breast was determined in square millimeters by manually delin-
eating the breast on the lateral projection of the preoperative digital
mammogram. Calculations were performed using the default radi-
ological software package available at each hospital. Last, post-
operativevariableswere scored for thepurposeof describingpatient
and tumor characteristics, including postoperative T-stage, post-
operative N-stage, weight of the excised lump, and tumor-to-lump
index (deﬁned as the maximum tumor diameter in millimeters
divided by the weight of the excised lump in grams).
Within the validation group, clinicopathological variables were
collected from patient ﬁles in the UMCG database. Variables were
scored identically to those in the modeling group.
Statistical analysis
The primary outcome for this study was the proportion of
positive surgical margins following lumpectomy. Multivariate lo-
gistic regression analysis (MVA) was used to test the association
between clinicopathological variables and the likelihood of positive
margins. Stepwise backward variable selection was performed to
determine informative variables based on the corrected Akaike’s
Information Criterion (AICc).13 The nested model with the lowest
AICc value was used to construct a graphical nomogram. A corre-
sponding web-based calculator was developed. Moreover, a second
calculator was developed including solely clinical and radiological
Table 1
Patient and tumor characteristics for the modeling and the validation group.
Characteristic Modeling group Validation group P-value
No. % No. %
No. of patients 1185 100 331 100
Age (years)
Mean (SE) 59.8 (0.31) 56.5 (0.63) <0.001a
Median 60.3 56.0
Range 27e95 26e91 <0.001b
40 39 3.3 28 8.5
41e69 919 77.6 255 77.0
70 227 19.2 48 14.5
Tumor size (mm)
Mean (SE) 15.6 (0.22) 15.2 (0.48) 0.107c
Median 14.0 13.0
Range 1.5e58.5 2.1e57.9 0.087
pT1a 54 4.6 22 6.6
pT1b 243 20.5 81 24.5
pT1c 599 50.5 164 49.5
pT2 284 24.0 62 18.7
pT3 5 0.4 2 0.6
Area on mammogram (mm2)
Mean (SE) 17,916 (6807) 17,575 (6937) 0.617
Median 17,163 16,498
Range 3551e46,895 5212e50,619 0.396
15000 450 38.0 138 42.4
15,000e25,000 554 46.8 142 44.7
25,000 181 15.3 45 13.8
Weight excised lump (g)
Mean (SE) 62.5 (39.7) 56.3 (40.0) 0.027
Median 53.0 47.0
Range 6e277 6e299 0.044
50 270 44.5 167 51.0
51e99 172 28.3 78 23.9
100 165 27.2 82 25.1
Tumor-to-lump index
Mean (SE) 0.338 (0.012) 0.354 (0.020) 0.503
Median 0.266 0.288
Range 0.02e3.67 0.02e4.41 0.132
0.25 278 45.8 121 39.2
0.25e0.50 228 37.6 135 43.7
0.50 101 16.6 53 17.2
Palpability 0.104
Palpable 637 53.8 195 58.9
Non-palpable 548 46.2 136 41.1
Tumor location <0.001
LOQ 122 10.3 42 12.7
UOQ 535 45.1 170 51.4
UIQ 189 15.9 50 15.1
LIQ 150 12.7 26 7.9
Central 103 8.7 6 1.8
Histological type 0.062
Ductal 957 80.8 286 86.4
Lobular 119 10.0 23 6.9
Speciﬁedd 109 9.2 22 6.6
Histological grade 0.214
Grade I 330 28.1 107 32.8
Grade II 531 45.2 133 40.7
Grade III 313 26.6 86 26.5
ER status 0.661
Positive 1002 85.3 276 84.4
Negative 172 14.7 51 15.6
PR status 0.443
Positive 750 71.4 226 69.1
Negative 300 28.5 101 30.9
Her2/neu receptor status 0.486
Positive 125 10.7 40 12.3
Negative 1041 89.3 290 87.7
Multifocal disease 0.170
Yes 47 4.0 19 5.7
No 1138 96.0 312 94.3
pN-stage 0.004
Positive 310 26.2 113 34.4
Negative 875 73.8 218 65.6
Prior surgery to the breast <0.001
Yes 46 3.9 34 10.3
(continued on next page)
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CNB.
Model performance was quantiﬁed in both the modeling group
and the validation group with respect to discrimination and cali-
bration. Discrimination was assessed by calculating the area under
the receiver-operating characteristic (AUROC) curve, resulting in
a so-called concordance index (c-index). Calibration was studied
graphically after grouping patients into deciles with respect to their
predicted probabilities and plotting the mean predicted probabil-
ities against the mean observed probabilities. Bootstrapping was
applied to calculate 95% conﬁdence intervals. Overall ﬁt of the
model was evaluated using the HosmereLemeshow goodness-of-
ﬁt test. Reported P-values are two-sided with alpha 5%.
Statistical analyses were performed using the statistical pack-
ages SPSS (SPSS for Windows, version 18.0.3, SPSS Inc., Chicago, IL)
and STATA Software, version 10.0 (StataCorp, College Station, TX).
Graphs were created using GraphPad Prism (GraphPad Prism for
Windows, version 5.00, GraphPad Software, San Diego, CA).
Results
Patient and tumor characteristics of the modeling and the val-
idation group are listed in Table 1.
Positive margins in BCT were present in 19.7% and 24.5% of the
patients in the modeling and validation group, respectively
(Supplemental Table 2). Marked differences between the modeling
and the validation group were observedwith respect to age, weight
of the excised lump, tumor location, pN-stage, prior surgery to the
breast, family history, BI-RADS classiﬁcation, and presence of DCIS.
Margin positivity ranged from 11% to 38% throughout the 20
institutions that constituted the modeling group. No difference was
observed between positive surgical margin rates from university-
afﬁliated and community hospitals (P ¼ 0.883). Moreover, no sig-
niﬁcant difference in the occurrence of positive margins was
observed between individual hospitals when evaluated using MVA
(P ¼ 0.282). Of the 233 patients with positive margins in the
modeling group, 92 (39.5%) patients had a relumpectomy with
clear margins, 2 (0.9%) patients had a second lumpectomy with
persistent positive margins, 16 (6.9%) patients underwent mastec-
tomy, and 123 (52.8%) patients had no further surgery despite
positive margins. Data on further surgical management were
available for all 233 (100%) patients.
Data on breast cup size was available for only 101 out of 1185
patients (8.5%) in the modeling group and 45 out of 331 patients
(13.6%) in the validation group (data not shown).We therefore used
the area of the breast on the digital mammogram to substitute for
cup size, as the correlation between both variables was strong
(Spearman’s rho: 0.893, P < 0.0001).
MRI was performed in 122 patients (10.3%) in the model group
for preoperative tumor assessment. Ultrasonography was per-
formed in the remaining 1064 patients (89.7%). In the validation
group, preoperative MRI was performed in 31 patients (9.4%), while
the remaining 300 patients (90.6%) had ultrasonography. Sentinel
lymph node biopsy was performed in the vast majority of patients,
including 1113 (93.9%) patients from the modeling group and 307
(92.7%) from the validation group. Axillary lymph node dissection
(ALND) was performed in 293 (24.7%) and 87 patients (26.3%),
respectively. A total of 221 (18.6%) and 63 (19.0%) patients received
an ALND in addition to an SLNB procedure.
Multivariate analysis
ThenestedMVAmodelwith the lowestAICc (959.6)was selected.
Clinicopathological variables constituting the ﬁnal model were
microcalciﬁcations, preoperative MRI, suspicion of multifocality,
Fig. 1. Discrimination of the ﬁnal model for the modeling and validation group. The
area under the receiver-operating characteristic (AUROC) curve, comparable to the
concordance index, indicates the discriminative power of the model. The reference line
indicates an AUROC value of 0.5, for which the probability of positive surgical margins
is equal to the toss of a coin. An AUROC value of 1.0 would resemble perfect
discrimination.
Table 1 (continued )
Characteristic Modeling group Validation group P-value
No. % No. %
No 1139 96.1 297 89.7
Family history <0.001
FDR 91 8.9 75 22.8
SDR 188 18.2 56 17.0
Negative 749 72.9 199 60.2
Referred from screening 0.755
Yes 578 49.1 158 47.7
No 601 50.9 172 52.3
BI-RADS classiﬁcation 0.001
IIe 3 0.3 8 2.5
III 93 8.1 31 9.7
IV 611 52.9 155 48.3
V 447 38.7 127 39.5
Preoperative MRI 0.680
Yes 122 10.3 31 9.4
No 1063 89.7 300 90.6
Microcalciﬁcations
Yes 245 20.8 74 22.4 0.542
No 937 79.2 257 77.6
DCIS component present <0.001
Yes 529 44.6 188 56.8
No 656 55.4 143 43.2
Breast density 0.816
0e25% 323 31.0 101 31.2
25e50% 467 44.9 146 45.0
50e75% 217 20.8 70 21.6
75e100% 34 3.3 7 2.2
Institution e
University-afﬁliated 642 54.2 331 100
Community hospital 543 45.8 e e
Abbreviations: ER, estrogen receptor; FDR, ﬁrst-degree relative; LIQ, lower inner
quadrant; LOQ, lower outer quadrant; MRI, magnetic resonance imaging; PR, pro-
gesterone receptor; SDR, second-degree relative; UIQ, upper inner quadrant; UOQ,
upper outer quadrant.
a Independent-samples t-test.
b Fisher’s exact test.
c Independent-samples t-test following logarithmic transformation to promote
data normality.
d Speciﬁed histological types included mucinous, medullary, tubular, and papil-
lary carcinomas.
e BI-RADS classiﬁcation II with malignancy proven by ﬁne needle aspiration or
core needle biopsy.
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the breast, histological type, histological grade, ER status and pres-
ence of DCIS. Corresponding odds ratios are listed in Table 2. Non-
signiﬁcant variables were included if they improved accuracy of
the model.Table 2
Preoperative clinical, radiological, and pathological variables included in the ﬁnal
model.
Predictor Odds
ratio
95% CI P-value
Suspicion of multifocal disease (vs. unifocal) 2.81 1.30e6.06 0.008
Preoperative MRI scan absent (vs. available) 1.80 1.02e3.18 0.043
Positive preoperative N-stage (vs. negative) 1.73 0.97e3.07 0.062
Non-palpable tumor (vs. palpable) 1.51 1.07e2.13 0.020
Microcalciﬁcations on mammogram
(vs. none)
1.37 0.95e2.00 0.094
Preoperative T2 stage (vs. T1) 1.33 0.87e2.02 0.185
Breast density on mammogram 1.22 1.00e1.49 0.053
Presence of DCIS component (vs. absence) 3.11 2.19e4.42 <0.001
Lobular histological type (vs. other) 2.90 1.71e4.91 <0.001
Positive ER status (vs. negative) 1.80 1.04e3.13 0.037
Elston III grade (vs. Elston I/II) 1.44 0.96e2.16 0.082
Reported odds ratios indicate a ratio of the probability of positive margins following
lumpectomy versus the probability of negative margins.Evaluation of the model
The model ﬁtted the data according to the HosmereLemeshow
goodness-of-ﬁt test (c2 ¼ 2.733, 8 degrees of freedom, P ¼ 0.950).
Discrimination (Fig.1) and calibration (Fig. 2) were ﬁrst assessed for
the modeling group. The c-index was calculated to be 0.70 (95% CI
0.66e0.74, P < 0.001). Calibration was considered adequate.
External validation on the UMCG dataset resulted in a c-index of
0.69 (95% CI 0.63e0.76, P < 0.001; Fig. 1). Calibration was consid-
ered acceptable (Fig. 2).Nomogram and web-based calculators
A graphical nomogram was developed based on the results of
MVA (Fig. 3). The underlying statistical formula was also imple-
mented in a web-based calculator, accessible at http://www.
breastconservation.com. Additionally, a second web-basedFig. 2. Calibration of the ﬁnal model in the modeling and validation group. All patients
were grouped into deciles (blue triangles and orange dots) based on their predicted
probabilities. Mean predicted probabilities were plotted against the actual incidence of
positive margins for each decile. Moreover, 95% conﬁdence intervals are shown for
both groups. The reference line represents perfect equality of observed frequencies and
predicted probabilities. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
Fig. 3. Nomogram including clinical, radiological, and pathological variables for predicting positive surgical margins following the ﬁrst attempt at lumpectomy. Instructions for use:
Locate the patient’s status on the ‘preoperative MRI’ axis. Draw a line straight upward to the ‘points’ axis to determine how many points are assigned to the individual patient.
Repeat this process for the axes below. Sum the points achieved for each variable and locate this sum on the ‘total points’ axis. From here, draw a line straight downward to obtain
the probability of positive surgical margins following lumpectomy for the individual patient. Note: Due to the relatively high frequency of false negative ﬁndings when assessing the
presence of co-existing DCIS in a core needle biopsy (CNB), absence of DCIS should be interpreted with caution. We therefore recommend to determine a suitable probability
interval by calculating the probability of positive surgical margins for both true and false negative outcomes. A user-friendly web-based version of the nomogram is available at
www.breastconservation.com.
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variables that can be used in the absence of a preoperative CNB.
Discrimination of this model ranged from 0.62 to 0.64 for the
modeling and validation group, respectively (Supplemental
Figure 1). Calibration was considered acceptable for both groups
(Supplemental Figure 2). Both calculators provide the user with
a patient-tailored estimation of the preoperative risk of positive
margins, stratiﬁed as low (<15%), intermediate (15e25%), or high
(>25%) risk. The calculators support Internet Explorer, Safari,
Firefox, and Google Chrome. An example on how to use the online
nomogram is provided on the website.
Discussion
We developed a nomogram and corresponding web-based cal-
culators to estimate the risk of positive margins following lump-
ectomy using clinicopathological variables. Variables predicting for
positive surgical margins on MVA included microcalciﬁcations on
mammogram (OR 1.37, P¼ 0.094), absence of preoperative MRI (OR
1.80, P¼ 0.043), suspicion ofmultifocality (OR 2.81, P¼ 0.008), non-
palpable tumor (OR 1.51, P ¼ 0.020), positive preoperative N-stage
(OR 1.73, P ¼ 0.062), large tumor size (OR 1.33, P ¼ 0.185), high
density of the breast (OR 1.22, P ¼ 0.053), lobular histological type
(OR 2.90, P < 0.001), high histological grade (OR 1.44, P ¼ 0.082),
positive ER status (OR 1.80, P ¼ 0.037) and presence of DCIS (OR
3.11, P < 0.001). In the absence of preoperative pathological vari-
ables (e.g. no CNB available), a second online calculator is available
at http://www.breastconservation.com that solely includes clinical
and radiological variables.
Assessment of pathological variables in the current study was
based on ﬁnal pathology due to the fact that ﬁne needle aspiration
biopsy instead of CNB was performed in the vast majority of pa-
tients. Nonetheless, CNB may provide important information on
preoperative prognostic factors and shows good correlation with
ﬁndings on ﬁnal pathology.14 Histological type can be accurately
predicted on CNB and is reported to be concordant with the sub-
sequent surgical specimen in 93e100% of the cases.15 For ER status,reported concordance rates between CNB and the surgical speci-
men range from 86% to 100%.16e18 Current evidence shows that
histological grade can be assessed on CNB and is concordant with
ﬁnal pathology in approximately 75% of the cases.19 The highest
level of agreement is achieved in high-grade carcinomas, with an
associated concordance rate of 84%.14 The presence of co-existing
DCIS can also be assessed on CNB and is associated with an
increased risk of positive margins.20e22 However, false negative
ﬁndings reported in the literature range from 36% to 54%, indicating
that the absence of DCIS in the CNB should be interpreted with
caution.21,23 The risk for false negative results of CNB can be
minimized by accurate targeting, sufﬁcient biopsy size, and
obtaining a larger number of cores.20 Jimenez et al.21 reported that
CNB predicts the presence of co-existing DCIS in the subsequent
surgical specimen with a sensitivity and speciﬁcity of 54% and 92%,
respectively. The corresponding negative and positive predictive
values were 70% and 85%. To account for the relatively high-risk of
false negative ﬁndings, we recommend determining a suitable
probability interval by calculating the probability of positive mar-
gins for both true and false negative outcomes when using our
nomogram (Fig. 3). The web-based calculator will automatically
provide the user with such a probability interval if applicable.
The ability to estimate the preoperative risk of positive margins
following lumpectomy could support clinicians in counseling pa-
tients regarding the likelihood of requiring further surgery, allow-
ing for a more patient-tailored approach. Although broadly
supported for positivemargins, some authors have also reported an
increased risk for LR in the case of close surgical margins.4,24
However, the importance of close margins is still a matter of
debate.25,26 Moreover, consensus over what is themost appropriate
margin is lacking, with deﬁnitions of close margins ranging from
<1 mm to <5 mm distance to the inked margin.27 Because the
clinical implications of close margins are uncertain, they were not
taken into account in the current study.
In patients identiﬁed as high-risk (>25%), we advise to perform
a preoperative MRI to assist the clinician in deﬁning the extent of
local disease and detect areas of co-existing high-grade DCIS that
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reported to reduce the risk of inadequate tumor excision.28 In the
current study, MRI was performed in those patients with preop-
erative suspicion of multifocal disease or with BRCA1 of BRCA2
mutations. Despite correction for these factors, MRI was found to
signiﬁcantly decrease the risk of positive margins (P ¼ 0.043;
Table 2). However, the true value of MRI in reducing the risk of
inadequate tumor excision in patients preoperatively identiﬁed as
high-risk needs to be assessed in future studies.
In addition, high-risk patients might beneﬁt from a more
extensive surgical excision. Lovrics et al.29 reported the amount of
breast parenchyma excised during BCS to be inversely correlated
with the likelihood of positive margins. In the current study, we
also found a signiﬁcant association between low tumor-to-lump
index (i.e. relatively small lump compared to size of the tumor)
and positive surgical margins (P ¼ 0.002). However, although
excising relatively voluminous specimens is more accurate in pre-
dicting margin status than any predictive model, it has profound
repercussions on cosmesis. To allow for relatively extensive exci-
sions while maintaining adequate cosmetic results, oncoplastic
surgery was suggested as a technique to minimize breast de-
formities by immediate reconstruction of large resection defects.30
The technique might be of particular value for those patients
identiﬁed as high-risk with our nomogram, although further
studies are needed to address this topic.
The rate of positive margins observed in the modeling (19.7%,
range: 11e38%) and the validation group (24.5%) are in line with
positivity rates reported in the literature.5 The slightly higher
positive margin rate in the validation group can partially be
explained by the high rate of co-existing DCIS (56.8% vs. 44.6% in
themodeling group, P< 0.001), which is known to increase the risk
of positive margins.31
Very recently, Shin et al.9 reported on a nomogram for pre-
dicting positive surgical margins after BCT. The nomogram was
based on retrospective single-center data derived from 1034
Korean breast cancer patients with invasive or in situ breast car-
cinoma. MVA indicated microcalciﬁcations (OR 1.57, P ¼ 0.034),
dense breasts (OR 4.52, P ¼ 0.005), 0.5 cm difference in tumor size
between MRI and ultrasonography (OR 10.00, P < 0.001), presence
of DCIS (OR 1.58, P ¼ 0.044), and lobular histological type (OR 3.99,
P ¼ 0.015) to be independent predictors for positive surgical mar-
gins. Validation was performed on an independent cohort of 563
patients. The concordance indices of the modeling and the vali-
dation groups were reported to be 0.82 (95% CI: 0.79e0.86) and
0.85 (95% CI: 0.80e0.89), respectively. Although the reported con-
cordance indices are relatively high when compared to the current
multicenter study, this difference may partly be explained by the
relative lack of heterogeneity in single-institution data, impairing
generalizability of the model.8 Our nomogram was constructed
based on multicenter data derived from 20 institutions, including
community-based and university-afﬁliated hospitals. Validation
was performed in an independent dataset that showed marked
differences when compared to the modeling group, providing
sufﬁcient data heterogeneity to assess generalizability of the
nomogram.
Several other nomograms are available in the ﬁeld of breast
cancer, including nomograms for predicting the likelihood of can-
cer spread to the sentinel lymph nodes,32 cancer spread to non-
sentinel lymph nodes,33 and the beneﬁt of systemic adjuvant
therapy (Adjuvant! Online).34 Moreover, Rudloff et al.35 developed
a nomogram (c-index: 0.704) for predicting the 5- and 10-year
probability for ipsilateral breast tumor recurrence after BCT for
ductal carcinoma in situ. The nomogram was developed on the
basis of unicenter data derived from 1681 patients and included ten
clinical, pathological, and treatment variables (age at diagnosis,family history, initial presentation, radiation, adjuvant endocrine
therapy, nuclear grade, necrosis, margins, number of excisions, and
year of surgery). Sanghani et al.36 constructed a web-based
nomogram for predicting the probability of ipsilateral breast tu-
mor recurrence after BCT. Data was derived from 7811 patients and
included both clinical and pathological variables (adjuvant RT or
endocrine therapy, age, margin status, number of excisions, and
treatment time period). Werkhoven et al.37 developed a compara-
ble nomogram (c-index: 0.68) based on data from 1603 patients.
Rouzier et al.38 developed several nomograms that can be applied
to predict the probability of successful BCT in patients who un-
derwent neo-adjuvant treatment.
We acknowledge that there are certain limitations to our study.
First, our study is subject to limitations that are inherent to retro-
spective data collection. Second, as discussed earlier, pathological
variables were obtained on ﬁnal pathology due to the fact that
preoperative CNB was not routinely performed in the vast majority
of patients. We were therefore unable to evaluate the concordance
between pathological variables as assessed on CNB and ﬁnal pa-
thology. However, numerous studies have evaluated this topic with
the majority of studies reporting good concordance rates. Third, we
used surgical margin status after the ﬁrst lumpectomy attempt as
a primary endpoint. Although information on positive margin rate
after a second lumpectomy might be of particular clinical interest,
the absolute number of patients with positive surgical margins
after a second lumpectomy in our study was considered insufﬁcient
to obtain adequate sample size for nomogram development. Larger
patient cohorts are therefore needed to address this topic. Last, our
nomogram is based on female Dutch inhabitants, who are primarily
Caucasian women. We therefore advise caution against extrap-
olation of the nomogram to different populations.
Conclusion
We developed and validated a nomogram to predict the prob-
ability of positive surgical margins following lumpectomy using
clinicopathological variables. Our nomogram could support clini-
cians in identifying high-risk patients who might beneﬁt from
preoperative MRI and/or oncoplastic surgery.
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